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use.9 Interestingly, much of the increase in amateur athletic use has 
been attributed to cosmetic instead of athletic improvements.10 These 
numbers indicate a concerning shift in use to beyond the realm of 
professional athletics. In addition, many “dietary supplements” used 
for athletic or cosmetic enhancement also discretely contain AAS, 
with contamination rates as high as 15%.11 Unfortunately, up to 50% 
of previous AAS users choose not to disclose their previous AAS use 
with physicians, potentially masking a clinician’s overall impression of 
the burden of AAS abuse.12
Both TRT and AAS use can lead to suppression of the 
hypothalamic–pituitary–gonadal (HPG) axis, resulting in a diminution 
of spermatogenesis and potential infertility. Spontaneous recovery 
of spermatogenesis after cessation of TRT or AAS is possible but 
may take several months to several years, and in some cases may be 
permanent.13–16 Taken together, the rising use of TRT and AAS in 
young- to middle-aged men, in conjunction with a societal shift toward 
greater paternal age,17 is creating an environment where clinicians are 
increasingly likely to encounter men seeking treatment for infertility 
related to prior TRT and/or AAS use or treatment for hypogonadism 
with interest in preserving their fertility. Meanwhile, men present to 
infertility specialists for vasectomy reversal (VR) at an average age of 
41 (n = 1300), some of whom may also suffer from hypogonadism and 
report current or previous TRT use.18 Therefore, clinicians need to be 
INTRODUCTION
In recent years, mass marketing has led to a greater public awareness 
of the age-related decline in serum testosterone levels and the 
association of hypogonadism with many already common medical 
comorbidities.1,2 This in part has fueled the growth of testosterone 
replacement therapy  (TRT) for hypogonadism, which experienced 
a 12-fold increase in sales worldwide from 2000 to 2011.3 The same 
trend occurred in the United States where the greatest increase was 
observed in younger men aged 40–49 years by 4-fold, resulting in an 
age group-specific prevalence of 2.3% in 2011.4 This is not surprising 
since approximately 7% of men less than 40 years and 38% of men older 
than 45 years demonstrate biochemical hypogonadism when defined 
as  <300  ng dl−1.1,5 As such, younger men are seeking treatment for 
hypogonadism with as many as 12.4% of all testosterone prescriptions 
occurring in men <39 years of age.6
Similar to TRT, there has also been an increase in the availability 
and use of anabolic-androgenic steroids (AAS). It is estimated that up 
to 3 million people use AAS in the Unites States alone, including up 
to 3% of high school age adolescents, 14% of collegiate athletes, and 
30% of community weight trainers; however, many of these estimates 
are based upon older data.7,8 A more recent review revealed that AAS 
use is a common cause of profound hypogonadism with up to one of 
five men seeking treatment for hypogonadism reporting prior AAS 
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keenly aware of the effects of TRT and AAS on spermatogenesis and 
what treatment options are available to reverse these effects to restore 
spermatogenesis.
NORMAL SPERMATOGENESIS
Normal spermatogenesis is dependent on appropriate signaling from 
the HPG axis. This signaling initially consists of a pulsatile release of 
gonadotropin-releasing hormone  (GnRH) from the hypothalamus 
via the portal system to the pituitary gland where stimulation 
results in gonadotropin release. Luteinizing hormone (LH) from the 
pituitary stimulates Leydig cells in the testis to produce testosterone 
and leads to intratesticular production of insulin-like growth 
factor 1 (IGF-1), which plays an integral role in Leydig cell LH receptor 
upregulation, steroidogenesis, and maturation.19,20 Follicle-stimulating 
hormone (FSH) from the pituitary stimulates Sertoli cells in the testis, 
which supports spermatogonial differentiation and maturation. Both 
FSH and maintenance of high intratesticular testosterone  (ITT) 
levels (50–100 fold higher than serum) in response to LH are critical for 
normal spermatogenesis to occur.21–24 Historically, Sertoli cell-produced 
androgen-binding protein was thought to be responsible for such high 
ITT levels, but recent data suggest that other factors are also involved.25 
Interestingly, animal studies have demonstrated that the absence of 
FSH signaling results in impaired spermatogenesis whereas loss of 
sufficiently high ITT levels results in the absence of spermatogenesis.26
Regulation of the HPG axis occurs via feedback inhibition. 
Endogenous testosterone directly inhibits GnRH and LH release 
at the hypothalamus and pituitary levels, respectively, leading to 
downstream attenuation of testosterone production. Testosterone 
also indirectly regulates gonadotropin secretion via estrogen, derived 
from testosterone conversion peripherally by aromatase enzyme. 
Estrogen exhibits a greater effect on LH secretion than FSH although 
additional FSH feedback inhibition occurs with inhibin B secreted 
from Sertoli cells. Inhibin B levels have been considered a surrogate 
for spermatogenesis; for example, men with spermatogenetic defects 
express lower inhibin B levels.27 Additional autocrine, paracrine, 
and endocrine factors within the hypothalamus, pituitary, and testis 
can function to further modulate the HPG axis in complex ways 
including endocannabinoids, GnRH, kisspeptin, norepinephrine, 
growth hormone, interleukins, and TGF-β.28 Therefore, the HPG axis 
represents a dynamic, but tightly regulated, system at multiple levels 
resulting in spermatogenesis, among other things.
INFLUENCE OF EXOGENOUS ANDROGENS ON 
SPERMATOGENESIS
The use of exogenous androgens can influence the HPG axis by similar 
mechanisms as endogenous testosterone by exerting negative feedback 
in a dose- and duration-dependent fashion, resulting in reductions in 
ITT, blunting of FSH production, and ultimately decrease or complete 
cessation of spermatogenesis.29 Data specifically describing the natural 
history of unassisted spermatogenesis recovery after long-term TRT 
are lacking, but such information can be extrapolated from the male 
contraceptive literature.16 Multiple and international trials using various 
testosterone preparations have been performed and demonstrate a 
median time to spermatogenesis suppression to <1 × 106 ml−1 sperm 
within 3.5 months. Alternatively, the same data demonstrate a median 
time to recovery of 20 × 106 ml−1 sperm ranging from 3 to 6 months, 
with probability estimates suggesting recovery in 67%, 90%, 96%, 
and 100% of men at 6, 12, 16, and 24  months, respectively, after 
discontinuation of testosterone exposure.13 These data also suggest 
that a longer exposure to exogenous testosterone, Asian ethnicity, 
and older age may result in a prolonged recovery time after treatment 
cessation.13,30–32 Importantly, one must consider that these data are 
carefully collected in men within the tightly controlled, clinical trial 
environment, and may not be generalizable. Certainly, men with a 
prior, multiple year history of TRT or AAS use may not expect the 
same rate of recovery.
AAS are synthetic derivatives of testosterone with chemical 
modifications intended to mimic the anabolic more than the androgenic 
effects of testosterone. Many abusers use “stacking” regimens with 
multiple, high-dose AAS agents to maximize muscle mass and weight 
gain, which are often “cycled” to minimize side effects. Nevertheless, 
AAS can still bind the androgen receptor within target cells and 
exert the same negative feedback effects as endogenous testosterone, 
often resulting in anabolic steroid-induced hypogonadism  (ASIH) 
and associated reductions in serum gonadotropin levels and 
ITT.9,15,21,33 With abnormally low ITT and FSH, these patients often 
exhibit azoospermia or oligospermia with reduced motility and/or 
morphology on semen analysis.15
Such effects on the HPG axis are potentially reversible with 
cessation of AAS use, but the time to recovery is highly variable and 
influenced by the dose and extent of stacking multiple AAS agents, 
duration of AAS use, and patient age.8,34 Data specifically looking at 
recovery of spermatogenesis after cessation of AAS are scant, but case 
reports suggest that recovery is feasible within 4–12 months although 
some patients may require up to 24–30 months to return to sperm 
concentrations of  >20  ×  106 ml−1.14,15,35–37 It cannot be understated 
that given the inherent variability in patient characteristics and AAS 
agent(s) used, a uniform recovery of the HPG axis cannot be expected 
in all patients.
PHARMACOLOGIC AGENTS TO RESTORE OR MAINTAIN 
SPERMATOGENESIS
Gonadotropins: hCG and FSH
Human chorionic gonadotropin (hCG) is a naturally occurring protein 
produced by the human placenta with a serum half-life of approximately 
36 h. Structurally, hCG shares an identical α-subunit with LH and FSH. 
However, hCG has a unique β-subunit that is virtually identical to the 
LH β-subunit except that it has an additional 24 amino acid tail at the 
amino terminus of the protein, which is highly glycosylated and leads to 
both a longer circulating half-life of hCG (~36 h) versus LH (~30 min) 
and increased receptor activity. The increased LH receptor activity, along 
with its longer half-life, makes it a clinically useful LH analog. Initially 
extracted from the urine of pregnant females, naturally occurring 
hCG has demonstrated efficacy at restoring spermatogenesis.38 
Newer, recombinant hCG has emerged and is considered equivalent 
to urinary sources pharmacologically although further study is 
warranted to confirm its equivalency to urinary forms in restoring 
spermatogenesis.39 Similarly, FSH has traditionally been derived from 
the urine of postmenopausal women in the form of human menopausal 
gonadotropin (HMG). A large proportion of naturally occurring HMG 
consists of copurified urinary proteins inactive at the FSH receptor, 
with a lesser proportion containing a blend of FSH, LH, and hCG.40 
Therefore, similar to hCG, refinements have led to production of highly 
purified urinary HMG, and more recently recombinant FSH (rFSH), 
to achieve higher specificity for the FSH receptor. To date, direct 
comparisons between the two have not occurred for use at inducing 
spermatogenesis in men, but data from use in women suggest that rFSH 
is equivalent to urinary preparations and can avoid the theoretical risk 
of Creutzfeld–Jakob disease;38,40 therefore, rFSH is the preferred method 
of pharmacologic delivery of FSH in men.
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Clinically, hCG has proven successful at inducing and/or 
maintaining spermatogenesis alone or in combination with FSH 
in patients with hypogonadotropic hypogonadism  (HH). HH is an 
uncommon but treatable cause of male factor infertility classically 
considered secondary to pathology of the hypothalamus or pituitary 
gland as seen with Kallman’s syndrome, Prader–Willi syndrome, 
panhypopituitarism from prolactinomas, tumors, infection or radiation, 
or idiopathic causes.21 Recently, recognition that the increasingly 
common use of exogenous TRT and/or AAS can also induce HH, 
also known as ASIH, with associated diminished spermatogenesis. 
Therefore, men with azoospermia or severe spermatogenic defects due 
to classic HH serves as a useful context in whom to appreciate the effect 
of gonadotropins upon spermatogenesis clinically. However, due to the 
uncommon prevalence of HH, high-quality data are lacking and most 
are limited to case reports and retrospective series.41
Historically, treatment approaches for HH have focused upon 
physiologic, pulsatile GnRH therapy to induce secondary sex 
characteristics and spermatogenesis with reported pregnancy rates 
as high as 80%.42,43 However, widespread use of pulsatile GnRH is 
inherently limited due to the need for an external pump for periodic 
hormone release, cost, and requirement of a functionally intact 
pituitary gland to appropriately respond to hypothalamic signals.44 
Alternatively, treatment with injectable gonadotropin regimens has 
demonstrated equivalent clinical efficacy compared with GnRH for 
triggering spermatogenesis based upon a recent meta-analysis.44 
Therefore, gonadotropins offer patients an efficacious and more 
convenient treatment approach.45 FSH given alone or in combination 
with testosterone has proven unsuccessful at inducing spermatogenesis 
or maintaining spermatogenesis in those previously induced with 
hCG/FSH  (hCG 1500  IU and HMG 150  IU both subcutaneous 
and 3  times per week), confirming the need for maintenance of 
elevated ITT.46 However, long-term use of hCG alone can induce 
spermatogenesis in up to 70% of patients, with a greater effect seen 
in men with initial testis length >4 cm, but further improvement is 
appreciated with the addition of FSH (HMG) suggesting a timelier 
recovery with both gonadotropins.47 The success of inducing 
spermatogenesis with a combination of hCG and FSH is supported 
by several studies  (Table  1).41,42,45,48–53 In these data, most begin by 
stimulating endogenous testosterone production with trial of hCG 
alone with doses ranging from 1500 to 5000 IU 2–3 times per week 
titrated according to serum testosterone levels. Most experts treat 
with hCG alone for 3–6 months after which a certain number of cases 
will result in spermatogenesis induction. In those without adequate 
spermatogenesis induction, treatment proceeds with the addition of 
FSH with doses ranging from 75 to 400 IU 2–3 times per week titrated 
according to semen analysis results. Success defined as induction of 
spermatogenesis with >1–1.5 × 106 ml−1 sperm was reported to occur 
in 44%–100% of patients treated for 6–144 months.52 Pregnancy rates, 
when reported, were observed in 40%–75% of patients usually at sperm 
concentration levels below “normal.”42,51,54 Factors predicting success 
include larger baseline testis volume, previous natural gonadotropin 
exposure  (normal puberty), and repeated treatment cycles whereas 
previous exogenous testosterone exposure and cryptorchidism 
portend a slower response although these findings are variable.42,55 It 
is important to consider these data are in men with HH due to classic 
causes and not patients with previous TRT/AAS use in whom better 
outcomes can theoretically be expected given the likelihood of normal 
pubertal development and HPG axis function at some point before 
TRT/AAS exposure.
Data specifically evaluating induction or maintenance of 
spermatogenesis in men with HH and azoospermia specifically 
due to previous TRT and/or AAS use is scarce (Table 2). In a study 
of normal men treated with TRT and randomized to concurrent 
administration of placebo or low-dose hCG (125, 150 or 500 IU) every 
other day, ITT levels were maintained in all hCG groups with levels 
closest to baseline normal in the 250 and 500 IU dose groups, thereby 
suggesting preservation of spermatogenesis.56 These data are supported 
by the finding from Depenbusch and colleagues that preservation 
of spermatogenesis is possible with hCG alone (500–2500 IU twice 
weekly based upon serum testosterone levels) in men with HH and 
azoospermia in whom spermatogenesis was previously initiated 
with hCG/FSH.57 However, in this study, spermatogenesis was only 
maintained “qualitatively,” in that mean sperm concentrations with 
hCG alone were 43% of levels previously achieved with spermatogenesis 
induction using a combination of hCG and FSH, suggesting both are 
needed for “quantitatively” normal spermatogenesis. Alternatively, 
a series of hypogonadal men wishing to preserve fertility while 
initiating TRT with different agents (transdermal gels and injections) 
demonstrated that low-dose hCG (500 IU every other day) preserves all 
aspects of analyzed semen parameters despite improvement in serum 
testosterone levels, and with no differences observed between different 
types of TRT agent used.58 A more recent multi-institutional series of 
men previously treated with TRT and established to be azoospermic or 
severely oligospermic (<1 × 106 ml−1) were given hCG 3000 IU every 
other day supplemented with either FSH, clomiphene citrate  (CC), 
tamoxifen, or anastrozole. This series demonstrated a mean recovery of 
spermatogenesis to a density of 22 × 106 ml−1 in 4 months.59 Similarly, a 
series of hypogonadal men on TRT seeking VR underwent “testicular 
salvage” with CC and hCG  (3000  IU every other day) before VR, 
resulting in normalization of HPG parameters and successful VR in 
Table 1: Gonadotropins for recovery of spermatogenesis in classic hypogonadotropic hypogonadism
hCG dose 
(IU)
Dose frequency 
(per week)
FSH dose 
(IU)
Dose frequency 
(per week)
Number of 
patients (n)
Duration 
(months)
Spermatogenesis 
recovery (%)
Pregnancy 
rate (%)
Burger and Baker 198450 1500–3000 1–2 200–400 3 45 6–28 - 50
Buchter et al., 199842 1000–2500 2 75–150 3 39 3–46 95 72
European Metrodin HP Study Group, 199848 2000 2 150 3 26 18 100 -
Burgues and Calderon, 199751 2500 2 150 3 60 6–9 80 -
Bouloux et al., 200349 1500–3000 2 150–225 3 30 11 44 -
Miyagawa et al., 200553 3000 2 75 2 36 12–48 50 -
Ishikawa et al., 200752 5000 3 150 3 28 6–144 64 -
Liu et al., 200945 1500–2000 2–3 75–150 3 75 6–35 90 -
Farhat et al., 201041 1500–5000 3 75–150 3 87 6–49 - 56
IU: international unit; hCG: human chorionic gonadotropin; FSH: follicle stimulating hormone
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83%.60 Finally, even less data are available to support gonadotropin 
use for restoration of spermatogenesis in azoospermic men with ASIH 
after AAS use. A few case reports indicate that hCG alone at variable 
doses (2000 IU 3 times per week to 10 000 IU once weekly)15,36,61 or 
both hCG (10 000 IU weekly) and FSH (75 IU daily) in combination62 
can restore spermatogenesis and in some cases lead to conception. 
Collectively, these data demonstrate that restoration and maintenance 
of spermatogenesis using gonadotropins is a successful strategy in men 
with prior TRT and/or AAS use, with results similar to those observed 
with gonadotropin use in men with classic HH.
Selective estrogen receptor modulators (SERMs)
SERMs are a group of medications that function to disrupt binding 
of estrogen at estrogen receptors in the hypothalamus through 
competitive antagonism. In men, normal binding of estrogen at these 
receptors functions as an indirect negative feedback mechanism of 
endogenous testosterone production to downregulate GnRH and 
subsequently pituitary gonadotropin production. Therefore, SERMs 
function to block estrogen feedback thereby increasing GnRH and 
gonadotropin production and ultimately increasing ITT levels in 
men without evidence of primary hypogonadism.16,63,64 Clinically, 
tamoxifen and CC are two of the most commonly used SERMs, with 
the former popularized by use in breast cancer treatment protocols 
and the latter popularized by its initial development for triggering 
ovulation in women. CC exists as a racemic mixture of shorter acting 
enclomiphene  (purely anti-estrogenic effects) and longer acting 
zuclomiphene  (both estrogen agonist and antagonist effects) and 
exhibits a serum half-life of approximately 5 days.65
CC use in men was first reported in 1966 for treatment of subfertile 
males to improve pregnancy rates based upon the theoretical benefit 
from its mechanism of action.66 Since then, it has been used off-label 
to treat various subpopulations of infertile men with reported dosing 
schedules ranging from 25 to 50 mg administered daily, every other day 
or cyclically with intermittent “off periods,” all of which may be titrated 
based upon serum testosterone levels.67–69 Several studies looking at 
CC use in men with secondary hypogonadism demonstrate clear 
improvement in serum testosterone levels, hypogonadal symptoms, 
and testosterone: estrogen ratios indicative of CC’s positive therapeutic 
effects on the HPG axis.69–71 Similarly, the use of CC in men with 
idiopathic oligospermia or azoospermia with or without hypogonadism 
has demonstrated favorable changes in hormone profiles and semen 
analyses, but data evaluating pregnancy rates have yielded conflicting 
results.72–74 Nonetheless, CC continues to be used clinically for the 
treatment of idiopathic male infertility and for the treatment of 
hypogonadal symptoms in men wishing to preserve spermatogenesis 
in the absence of randomized controlled data. Overall, CC is well 
tolerated and considered safe in men who tend to experience much 
fewer side effects than seen with CC use in women.75,76 However, 
isolated case reports have demonstrated the possibility of developing 
azoospermia with CC use in oligospermic men that is reversible with 
CC cessation.77 For this reason, it is necessary to inform patients of 
its potentially unpredictable results, and follow-up serum laboratory 
studies and semen analyses are important during treatment with CC.
Literature assessing CC use to restore spermatogenesis in 
oligospermic and azoospermic men with HH after TRT and/or AAS use 
is very limited (Table 2). Case reports of CC use at higher doses (100 mg 
daily) in young men with ASIH resulted in normalization of the HPG 
axis within 2–3 months, but spermatogenesis was not evaluated.78,79 A 
small and retrospective case series looking at two men with idiopathic, 
acquired HH with oligospermia and azoospermia, and one man with 
ASIH and azoospermia who were each given CC 50 mg 3 times per 
week found 100% recovery of serum gonadotropins, testosterone, 
and spermatogenesis within 3 months and a 66% pregnancy rate.80 
More recently, a larger retrospective series of 63 men given a 
combination of hCG 3000 IU 3 times per week and CC or tamoxifen 
demonstrated recovery of spermatogenesis to >1 × 106 ml−1 sperm in 
98% of men in 4–5 months, with a mean initial sperm concentration 
of 22.6 × 106 ml−1.59 Similarly, a testicular salvage regimen of CC 25 mg 
daily or combination with hCG 3000 IU every other day for six men 
with a history of TRT presenting for VR resulted in normalization of 
the HPG axis and successful VR in 83% of patients.60
CC consists of a racemic mixture of zuclomiphene and enclomiphene 
with the latter exhibiting purely anti-estrogenic effects with a relatively 
shorter half-life (10.5 h) than CC.81 Therefore, more promising than 
CC are the recently reported results using enclomiphene citrate (EC) 
in men. Several positive clinical trials have been performed, but official 
Table 2: Commonly used pharmacologic agents for maintenance or restoration of spermatogenesis after anabolic-androgenic steroid or exogenous 
testosterone use
Medication Maintenance dose Restoration dose Combination therapy Dosing considerations
Gonadotropin analogs
hCG 500–2500 IU 2x/wk57
500 IU every other day58
3000 IU every other day59
10 000 IU 3x/wk62
1000–3000 IU 3x/wk34
Yes, with
FSH57,59,62
SERM59,60
AI59
Titrate dose based upon response of 
testosterone levels
Recombinant FSH - 75 IU daily62
150 IU 3x/wk57
75–150 IU 3x/wk59
Yes, with
hCG
Typically initiate with or add to hCG 
regimen and titrate dose every 
3 months based upon semen analysis
SERM
Clomiphene citrate 25 mg daily or 50 mg every other day
Note no data exist to support this 
indication
50 mg 3x/wk80
25–50 mg every other day59,60
100 mg daily78,79
Yes, with
hCG59
Titrate dose based upon response of 
testosterone levels
Monitor semen parameters
Enclomiphene 12.5–25 mg daily84 25 mg daily82 - Phase III data and FDA approval pending
AI
Anastrozole - 1 mg daily59,86–88 Yes, with
hCG59
Useful as an adjunctive therapy in 
scenarios of T: E <10:1
Letrozole - 2.5 mg daily89 - Beware of possible hepatotoxicity and 
pulmonary embolism risk
2x: 2 times; 3x: 3 times; mg: milligram; wk: week; IU: international unit; hCG: human chorionic gonadotropin; FSH: follicle stimulating hormone; SERM: selective estrogen receptor 
modulators; AI: aromatase inhibitors; FDA: Food and Drug Administration
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FDA approval is still pending. A phase IIB clinical trial followed 12 men 
previously treated with TRT for >6 months and documented HH with 
oligospermia or azoospermia were randomized to EC 25 mg daily versus 
topical testosterone gel for 6 months. The study demonstrated equivalent 
responses in serum testosterone levels in both arms, and statistically 
significant improvements in semen parameters were appreciated in the 
EC group (P = 0.004).82 Similarly, another phase II trial looking at EC use 
in men with secondary hypogonadism demonstrated increases in serum 
testosterone and gonadotropin levels within 2 weeks of treatment.83 
Finally, the most recent phase IIB trial studied 73 hypogonadal men 
with normal spermatogenesis who were randomized to EC 12.5 mg 
or 25 mg daily, topical TRT, or placebo. Equivalent increases in serum 
testosterone, estradiol, and LH levels among TRT and EC groups were 
demonstrated, but an increase in oligospermia and azoospermia was 
observed in the TRT group whereas spermatogenesis was preserved 
in the EC and placebo groups.84 Therefore, EC represents an exciting 
new treatment on the horizon for restoration and preservation of 
spermatogenesis in hypogonadal men, which will hopefully obtain 
future FDA approval pending results from upcoming phase III studies.
Aromatase inhibitors (AIs)
AIs are a class of medications FDA approved for the treatment of 
early- and late-stage breast cancer and historically include nonselective 
steroidal, and highly selective nonsteroidal agents, including anastrozole 
and letrozole. AIs function by inhibiting the aromatase enzyme, which 
is a cytochrome P450 converter of testosterone-to-estrogen within 
the testes, liver, brain, and adipose tissues.16 Estrogen is an indirect 
mediator of testosterone feedback inhibition of the HPG axis. Therefore, 
aromatase inhibition in men can result in decreased estrogen levels and 
ultimately increased gonadotropin production. Their use clinically in 
men is off-label and has focused upon improving male infertility and 
symptoms of hypogonadism, particularly in obese men or in those with 
a serum testosterone-to-estrogen (T/E) ratios <10 where improvements 
of approximately 77% have been observed.64 In addition, AIs can be 
prescribed for use with exogenous testosterone or hCG to mitigate side 
effects of hyperestrogenemia such as gynecomastia.
Studies evaluating the use of older AI agents in oligospermic men 
have suggested improvement in T/E ratios and spermatogenesis but 
randomized controlled data using testolactone failed to support these 
findings.85 However, recent data by Raman and Schlegel compared 
testolactone  (500–1000  mg twice daily) to a more selective AI, 
anastrozole  (1  mg daily), in subfertile men. Patients had abnormal 
T/E ratios along with idiopathic oligospermia or azoospermia, and 
the study demonstrated a statistically significant improvement in T/E 
ratios and spermatogenic parameters with anastrozole in those with 
oligospermia, but not those with azoospermia.86 Similar success adding 
anastrozole (1 mg daily) to existing treatment in men with idiopathic 
oligospermia and abnormally low T/E ratios unresponsive to 3 months 
of treatment with tamoxifen alone demonstrates improvement in 
sperm concentration and motility.87 The previous suggestion of AI 
failure at improving semen parameters in men with nonobstructive 
azoospermia by Raman and Schlegel has been challenged by recent 
data showing improved success rates with microsurgical testicular 
sperm extraction in men with nonmosaic Klinefelter’s syndrome and 
normalized serum testosterone levels after treatment with anastrozole 
preoperatively.88 The use of letrozole  (2.5  mg daily), a newer and 
more selective AI, has demonstrated improvements in T/E ratio and 
spermatogenic parameters similar to anastrozole with up to 20% 
spontaneous pregnancy rate for oligospermic men and 24% return of 
sperm to the ejaculate of previously azoospermic men.89
The use of AIs in infertile men with previous TRT and/or AAS 
use has not been reported in prospective trials. The aforementioned 
retrospective series from Wenker et  al. evaluating hCG used 
concurrently with SERMs, AIs, and FSH, in men with previous TRT 
use and severe oligospermia or azoospermia demonstrated an overall 
98% success rate at recovering spermatogenesis and 38% spontaneous 
pregnancy rate, with no differences between the type of supplemental 
therapy given with hCG or type of TRT used (Table 2).59 More recently, 
a study of 26 hypogonadal, infertile, nonazoospermic men randomized 
to CC 25 mg daily or anastrozole 1 mg daily for 6 weeks was performed 
and demonstrated improvements in both overall testosterone levels 
and T/E ratios, but CC had a greater impact on testosterone levels 
and anastrozole had a greater impact on T/E ratio.90 Therefore, in 
hypogonadal men with T/E ratios  <10, CC and AIs may be used 
concurrently to achieve the best result; however, this theoretically 
beneficial pharmacologic combination has not been reported in 
prospective studies, but anecdotally may prove useful.
Overall, the use of AIs is generally well tolerated in women, 
but elevated liver enzymes have been reported in up to 17% of 
the patients suggesting caution in those with a history of hepatic 
dysfunction. A series evaluating anastrozole for treatment of secondary 
hypogonadism in 69 older men followed for 1  year confirmed a 
generally low rate of adverse events although one instance each of 
new diagnosis hepatitis, pulmonary embolism, and embolic stroke was 
reported.91 A similar observation of pulmonary embolism incidence 
was confirmed in a more recent series after only 12 weeks of treatment.90 
In addition, some data have suggested potentially worse skeletal bone 
health with anastrozole use in older men, presumably based upon 
lower estrogen levels.92 Taken collectively, AIs may result in a positive 
influence on the HPG axis after TRT or AAS use, but in the absence 
of more robust clinical data and an uncertain side effect profile with 
long-term use, AI use may be limited to an adjunctive role only in 
those who have abnormally low T/E ratios.
CLINICAL SCENARIOS
Men with infertility related to previous TRT and/or AAS use can 
present clinically in a number of scenarios that can be challenging 
to navigate as a clinician. In this review, we have provided the 
pathophysiology of TRT and AAS effects on normal spermatogenesis 
and the pharmacologic tools available to potentially reverse these 
effects. Certain clinical scenarios are commonly encountered, and a 
brief discussion of these authors’ recommendations for treatment in 
each scenario follows.
Infertile male with a recent history or current use of TRT and/or AAS
A patient who presents for treatment of male factor infertility, indicated 
by oligospermia or nonobstructive azoospermia, who either reports a 
recent history or current use of TRT and/or AAS is a common scenario 
faced by a male fertility specialist. Several options could be discussed 
depending on the severity of his hypogonadal symptoms, timing in 
which he and his partner wish to achieve pregnancy, and assuming 
there is no clinical evidence of primary hypogonadism.
If the patient and his partner are willing to wait and his 
hypogonadal symptoms are manageable without TRT or AAS, the 
patient could simply discontinue the use of TRT or AAS to allow 
spontaneous recovery. Data from the male contraception literature 
indicate a reasonable probability of recovery in 67%, 90%, 96%, and 
100% of men at 6, 12, 16, and 24 months, respectively, with a median 
time to recovery of 20 × 106 ml−1 sperm in 3–6 months.13,30,31 Yet, many 
men will not tolerate discontinuation either due to severe hypogonadal 
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symptoms, uncertainty of recovery, and/or timing issues, and these 
men may require some form of alternate androgen supplementation. 
Therefore, one could administer gonadotropin analogs similar to 
those implemented in patients with HH. Assuming there is no major 
component of primary hypogonadism, this option is safe, would treat 
hypogonadal symptoms, and would hasten the time to recovery. It is 
reasonable to start with hCG 3000 IU subcutaneous injection 3 times 
weekly for 3 months with additional titration pending interim serum 
testosterone levels although the optimal hCG dose has not been clearly 
established. If at 3 months seminal parameters have not improved, one 
could add FSH. A typical starting dose is rFSH 75 IU subcutaneous 
injection 3 times weekly.
During gonadotropin therapy, adjunctive treatments with AIs or 
SERMs are typically implemented. Such an approach has demonstrated 
excellent results on average within 4–5 months.59 CC 25 mg daily or 
50 mg every other day, titrated up to 50 mg daily, may demonstrate 
improvement in seminal parameters in as little as 3  months for 
men with HH. CC is cost effective and has been more effective as a 
combined therapy in this setting, with less extensive data to support it 
as a monotherapy.80 If the patient exhibits a low T/E ratio, an AI could 
be prescribed, with anastrozole 1 mg oral twice weekly is a reasonable 
starting dose that may be titrated up or down according to the response.
Maintenance of spermatogenesis before beginning or during TRT 
or AAS use
A second scenario is a patient who wishes to preserve existing 
spermatogenesis before beginning TRT or AAS use. Maintenance of 
normal ITT levels is critically necessary to maintain spermatogenesis. 
hCG has proven to maintain ITT levels with doses as low as 500 IU 
every other day.56,57 Clinical data evaluating higher doses of hCG given 
as monotherapy (500–2500 IU twice weekly), or low-dose hCG (500 IU 
every other day) in combination with TRT, have demonstrated 
satisfactory results for maintaining spermatogenesis,57,58 and either 
would be a good choice as recommended by these authors.
Alternatively, CC is commonly used as an alternative to TRT to 
treat hypogonadism in men wishing to preserve spermatogenesis. The 
ability to take an oral medicine that is relatively inexpensive and has 
good long-term safety data and is clinically efficacious at ameliorating 
hypogonadal symptoms is clearly advantageous.69,71 However, data 
are currently not available specifically evaluating CC in this manner, 
and randomized controlled trials are needed. The newer SERM on 
the horizon, EC, has been studied in the phase II clinical trial setting 
specifically demonstrating preservation of spermatogenesis on semen 
analysis while satisfactorily improving hypogonadal symptoms and 
serum testosterone levels, and phase III data is pending.82,84 Finally, AIs 
such as anastrozole or letrozole may be helpful in this clinical scenario 
for patients who are obese and/or exhibit a low T/E ratio <10:1.
Patient presenting for vasectomy reversal with a history of secondary 
hypogonadism or previously treated with TRT
A final scenario is a patient who presents for VR for which he is 
otherwise a good candidate, who has a history of hypogonadism 
currently or previously treated with TRT. Such a scenario is difficult 
because the current status of his spermatogenesis may be deduced only 
by careful history, testis volume on clinical exam, and serum hormone 
testing of the HPG axis. Spermatogenesis cannot be definitively 
evaluated without testis biopsy in the setting of a vasectomized patient. 
Likewise, the risk of proceeding with VR under the assumption of 
normal spermatogenesis based upon physical exam poses an increased 
risk of intraoperative difficulty evaluating vasal fluid for sperm and 
ultimately a higher risk of failure. Data on this topic are limited, but a 
recent small, retrospective series was published of six men with median 
age of 39 using a preoperative testicular salvage regimen of CC 25 mg 
daily with or without hCG 3000 IU every other day for 3 months after 
discontinuation of TRT. After testicular salvage therapy, the authors 
demonstrated an 83% overall success rate with VR, which was 100% 
if at least one vasovasostomy was performed.60 In that case series, if 
improvement in testicular volume on physical exam and increase in 
gonadotropin levels was appreciated, VR was performed; however, 
testicular sperm aspiration was performed in two of the six men to 
confirm spermatogenesis before VR due to insufficient testis volume 
improvement and/or lack of improvement of the HPG axis on serum 
hormone testing. Such an approach for the vasectomized patient 
before VR has otherwise not been previously described, nor has the 
use of hCG and CC outside of another retrospective study,59 but the 
results appear promising. These authors would consider treatment 
with CC 25 mg daily with hCG 3000 IU every other day for 3 months, 
with a reassessment of the HPG axis and physical exam to ensure 
improvement before VR.
CONCLUSIONS
In the era of rising testosterone use and greater awareness of AAS use 
in younger men, clinicians need to be aware of the detrimental effects 
of these agents on spermatogenesis. As the body of evidence grows 
in support of restorative therapies for recovery of spermatogenesis 
in this patient population, it is important to be familiar with the 
various treatment options, their effects on the HPG axis, and when 
to use them. A historical perspective on gonadotropin use for HH is 
helpful to interpret the current use of gonadotropins for restoration 
or maintenance of spermatogenesis. Likewise, understanding the 
clinical use and effectiveness of CC and other SERMs helps lay the 
foundation for implementation of newer agents such as EC. Despite 
off-label use of each restorative agent discussed herein, a definite lack of 
high quality data, and the general understanding of male reproductive 
endocrinology still in its infancy, the field of male infertility is rapidly 
advancing in this area as the importance of restoring and maintaining 
spermatogenesis in men before, during, and after TRT is becoming 
fully realized.
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